Billets de Michelle Dawson

Billet publié sur Twitter/X le 24/04/2023 15:24

Twitter/X Publication avec DOI crossref Extrait cité dans le billet Lien intégré au billet

Liens cités structurés

1 ressource citée

Publication avec DOI Récupéré Publication crossref

Daniela R. Junqueira, Liliane Zorzela, Susan Golder, Yoon Loke, Joel J. Gagnier, Steven A. Julious, Tianjing Li, Evan Mayo-Wilson, et al. (2023). CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials. Journal of Clinical Epidemiology, 158, 149-165. Elsevier BV.

Date de publication
juin 2023
Identifiant
10.1016/j.jclinepi.2023.04.005
Auteurs
Daniela R. Junqueira, Liliane Zorzela, Susan Golder, Yoon Loke, Joel J. Gagnier, Steven A. Julious, Tianjing Li, Evan Mayo-Wilson, Ba Pham, Rachel Phillips, Pasqualina Santaguida, Roberta W. Scherer, Peter C. Gøtzsche, David Moher, John P.A. Ioannidis, Sunita Vohra, Stephen Evans, Ann Fonfa, Thomas A. Lang, Elizabeth Loder, Laura Weeks
Source
Journal of Clinical Epidemiology
Détails
158, 149-165
Type de référence
article
Éditeur
Elsevier BV
Source de métadonnées
crossref

Résumé

Randomized controlled trials remain the reference standard for healthcare research on effects of interventions, and the need to report both benefits and harms is essential. The Consolidated Standards of Reporting Trials (the main CONSORT) statement includes one item on reporting harms (i.e., all important harms or unintended effects in each group). In 2004, the CONSORT group developed the CONSORT Harms extension; however, it has not been consistently applied and needs to be updated. Here, we describe CONSORT Harms 2022, which replaces the CONSORT Harms 2004 checklist, and shows how CONSORT Harms 2022 items could be incorporated into the main CONSORT checklist. Thirteen items from the main CONSORT were modified to improve harms reporting. Three new items were added. In this article, we describe CONSORT Harms 2022 and how it was integrated into the main CONSORT checklist and elaborate on each item relevant to complete reporting of harms in randomized controlled trials. Until future work from the CONSORT group produces an updated checklist, authors, journal reviewers, and editors of randomized controlled trials should use the integrated checklist presented in this paper.

Auteur·ices de l’étude dans cette référence citée